Alterations of Gut Microbiome, Function, and Its Intervention After Defunctioning Ileostomy
NCT ID: NCT05759741
Last Updated: 2023-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
64 participants
INTERVENTIONAL
2023-01-17
2024-07-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Effects of Different Enterostomy Approaches
NCT05853094
Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer
NCT06375434
The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients
NCT06204497
Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer
NCT06898359
Stoma Discharge Reinfusion After Sphincter Preservation for Middle and Low Rectal Cancer
NCT05461248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MIYAIRI 588 group
4 tablets of MIYAIRI 588 were inserted into distal ileostomy once a week for 6 months.
MIYAIRI 588
4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
control group
The anastomosis stoma was followed up monthly in the outpatient department
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIYAIRI 588
4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients voluntarily sign informed consent.
Exclusion Criteria
2. Patients with inflammatory bowl disease.
3. Patients need to be on antibiotics/other probiotics for a long time.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huashan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianbin Xiang
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huashan hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY2022-1095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.